Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.
Barry, Robert; Tallouzi, Mohammad; Bucknall, Nick; Mathers, Jonathan; Murray, Philip; Calvert, Melanie; Moore, David; Denniston, Alastair

DOI: 10.1002/14651858.CD012577.pub2

License: None: All rights reserved

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Link to publication on Research at Birmingham portal

Publisher Rights Statement:
Checked for eligibility 15/01/2019

"This Cochrane Review was published in the Cochrane Database of Systematic Reviews 2018. Issue 12. Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Cochrane Review."


General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

• Users may freely distribute the URL that is used to identify this publication.
• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
• Users may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
• Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 20. Nov. 2020
Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis (Review)

Barry RJ, Tallouzi MO, Bucknall N, Mathers JM, Murray PI, Calvert MJ, Moore DJ, Denniston AK

Barry RJ, Tallouzi MO, Bucknall N, Mathers JM, Murray PI, Calvert MJ, Moore DJ, Denniston AK.
Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis. 
DOI: 10.1002/14651858.CD012577.pub2.

www.cochranelibrary.com
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>1</td>
</tr>
<tr>
<td>Abstract</td>
<td>1</td>
</tr>
<tr>
<td>Plain Language Summary</td>
<td>2</td>
</tr>
<tr>
<td>Background</td>
<td>3</td>
</tr>
<tr>
<td>Objectives</td>
<td>5</td>
</tr>
<tr>
<td>Methods</td>
<td>5</td>
</tr>
<tr>
<td>Results</td>
<td>8</td>
</tr>
<tr>
<td>Figure 1</td>
<td>10</td>
</tr>
<tr>
<td>Discussion</td>
<td>11</td>
</tr>
<tr>
<td>Authors' Conclusions</td>
<td>12</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>12</td>
</tr>
<tr>
<td>References</td>
<td>12</td>
</tr>
<tr>
<td>Characteristics of Studies</td>
<td>16</td>
</tr>
<tr>
<td>Appendices</td>
<td>17</td>
</tr>
<tr>
<td>Contributions of Authors</td>
<td>22</td>
</tr>
<tr>
<td>Declarations of Interest</td>
<td>22</td>
</tr>
<tr>
<td>Sources of Support</td>
<td>22</td>
</tr>
</tbody>
</table>
Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis

Robert J Barry1, Mohammad O Tallouzi2, Nick Bucknall3, Jonathan M Mathers2, Philip I Murray1, Melanie J Calvert4,5, David J Moore6, Alastair K Denniston7

1 Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 2 Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. 3 Shrewsbury, UK. 4 Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 5 NIHR Birmingham Biomedical Research Centre and NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham, Birmingham, UK. 6 Institute of Applied Health Research, University of Birmingham, Birmingham, UK. 7 Department of Ophthalmology, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Contact address: Robert J Barry, Academic Unit of Ophthalmology, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK. r.j.barry@bham.ac.uk.

Editorial group: Cochrane Eyes and Vision Group.


Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Non-infectious uveitis describes a heterogenous group of ocular disorders characterised by intraocular inflammation in the absence of infection. Uveitis is a leading cause of visual loss, most commonly due to uveitic macular oedema (UMO). Treatment is aimed at reducing disease activity by suppression of the intraocular inflammatory response. In the case of macular oedema, the aim is to restore macular architecture as quickly as possible, in order to prevent irreversible photoreceptor damage in this area. Acute exacerbations are typically managed with corticosteroids, which may be administered topically, locally or systemically. Whilst these are often rapidly effective in achieving disease control, long-term use is associated with significant local and systemic side effects, and 'steroid sparing agents' are typically used to achieve prolonged control in severe or recalcitrant disease. Anti-tumour necrosis factor (TNF) drugs block a critical cytokine in the inflammatory signalling process, and have emerged as effective steroid-sparing immunomodulatory agents in a wide range of non-ocular conditions. There is mechanistic data to suggest that they may provide a more targeted approach to disease control in UMO than other agents, but to date, these agents have predominantly been used 'off label' as the majority are not licensed for ocular use. This review aims to summarise the available literature reporting the use of anti-TNF therapy in UMO, thus developing the evidence-base on which to make future treatment decisions and develop clinical guidelines in this area.

Objectives

To assess the efficacy of anti-TNF therapy in treatment of UMO.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 2), which contains the Cochrane Eyes and Vision Trials Register; Ovid MEDLINE; Ovid Embase; LILACS; Web of Science Conference Proceedings Citation Index-Science (CPCI-S); System for Information on Grey Literature in Europe (OpenGrey); the ISRCTN registry; ClinicalTrials.gov and the WHO ICTRP. The date of the search was 29 March 2018.

Selection criteria
We planned to include all relevant randomised controlled trials assessing the use of anti-TNF agents in treatment of UMO. No limits were applied to participant age, gender or ethnicity. The primary comparisons of this review were: anti-TNF versus no treatment or placebo; anti-TNF versus another pharmacological agent; comparison of different anti-TNF drugs; comparison of different doses and routes of administration of the same anti-TNF drug. The primary outcome measure that we assessed for this review was best-corrected visual acuity (BCVA) in the treated eye. Secondary outcome measures were anatomical macular change, clinical estimation of vitreous haze and health-related quality of life.

Data collection and analysis
Two review authors independently screened titles and abstracts retrieved through the database searches. We retrieved full-text reports of studies categorised as 'unsure' or 'include' after we had reviewed the abstracts. Two review authors independently reviewed each full-text report for eligibility. We resolved discrepancies through discussion.

Main results
We identified no completed or ongoing trial that was eligible for this Cochrane Review.

Authors' conclusions
Our review did not identify any evidence from randomised controlled trials for or against the role of anti-TNF agents in the management of UMO. Although there are a number of high-quality randomised controlled trials that demonstrate the efficacy of anti-TNF agents in preventing recurrence of inflammation in uveitis, the reported study outcomes do not include changes in UMO. As a result, there were insufficient data to conclude whether there was a significant treatment effect specifically for UMO. Future trials should be designed to include quantitative measures of UMO as primary study outcomes, for example by reporting the presence or absence of UMO, or by measuring central macular thickness for study participants. Furthermore, whilst UMO is an important complication of uveitis, we acknowledge that uveitis is associated with many significant structural and functional complications. It is not possible to determine treatment efficacy based on a single outcome measure. We recommend that future reviews of therapeutic interventions in uveitis should use composite measures of treatment response comprising a range of potential complications of disease.

PLAIN LANGUAGE SUMMARY
Anti-tumour necrosis factor medication for treating swelling at the back of the eye (macular oedema) due to inflammatory eye disease (uveitis)

What is the aim of this review?
The aim of this Cochrane Review was to find out whether a new class of drugs (anti-tumour necrosis factor agents) is effective in treating swelling at the back of the eye (macular oedema) caused by inflammation in the eye (uveitis). Cochrane Review authors searched for all relevant studies to address this question, but found no suitable studies for inclusion.

Key messages
There is currently no evidence for or against the use of anti-tumour necrosis factor agents in treatment of macular oedema in uveitis.

What was studied in this review?
Uveitis is a group of eye conditions where there is inflammation within the eye. If there is inflammation at the back of the eye (macula) this can cause swelling (macular oedema). Macula oedema can lead to loss of vision.

Uveitis is often treated with steroids to control the inflammation and avoid damage to the eye. But steroids have potentially serious side effects, and doctors do not recommend long-term use. 'Steroid-sparing agents' are medications with similar anti-inflammatory effects.
to steroids, but with fewer side effects. They are preferred when people with uveitis need long-term treatment. Anti-tumour necrosis factor agents are a new type of steroid-sparing agent. They have been used for other conditions. Cochrane researchers wanted to find out if these agents are useful in the treatment of macular oedema in uveitis.

What are the main results of the review?

Cochrane Review authors searched multiple electronic databases for studies of the use of anti-tumour necrosis factor medications in macular oedema due to uveitis. They found no relevant studies. There are some studies that show that these drugs are effective in controlling inflammation in the eye, but none of these specifically investigated macular oedema. More research is needed to help inform decision-making in this area.

How up-to-date is this review?

Cochrane Review authors searched for studies that had been published up to 29 March 2018.

Background

Description of the condition

Uveitis describes a group of disorders characterised by intraocular inflammation. Uveitis is the fifth most common cause of visual loss in high-income countries, accounting for approximately 10% to 15% of total blindness (Durani 2004; William 2007). This figure rises to 25% in low- and middle-income countries (Abdulaal 2015; Rao 2013). Although uveitis may affect any age group, it peaks in the working-age population, with no significant difference between sexes (Acharya 2013). The annual incidence of uveitis is estimated at 17.4 to 52.4 per 100,000 people with a prevalence of around 38 to 114.5 per 100,000 general population (Durani 2004; Griz 2004; Suhler 2008; William 2007).

Uveitis often occurs in younger people in the working population compared to other eye diseases such as cataracts and age-related macular degeneration, so the condition has a huge impact in terms of years of potential blindness and economic cost (Durani 2004). Uveitis may be classified anatomically as anterior uveitis, intermediate uveitis, posterior uveitis or pan-uveitis (Bloch-Michel 1987; Deschenes 2008). It may arise from a range of different infectious and non-infectious aetiological sources. The focus of this review is non-infectious uveitis, most of which is thought to be autoimmune (or at least auto-inflammatory) and usually requires immunosuppressive treatment (Barry 2014; Van Gelder 1999). Non-infectious uveitis may be associated with a range of inflammatory syndromes, including ankylosing spondylitis, Behcet’s disease, sarcoidosis and multiple sclerosis (Lee 2014a; Lee 2014b; Takeuchi 2013).

The leading cause of sight loss in people with uveitis is macular oedema, known in this context as uveitic macular oedema (UMO) (Durani 2004; Lardenoye 2006). Macular oedema describes the accumulation of fluid in the retina (the light-sensitive inner lining of the eye) in the area that provides central vision known as the ‘macula’ (Davis 2010; De Smet 2010). Macula oedema is more common in forms of uveitis affecting the more posterior structures in the eye, namely intermediate and posterior uveitis and pan-uveitis; collectively these are sometimes referred to as posterior segment-involving uveitis. Macular oedema can also occur in association with anterior uveitis (Kaiser 2009).

Macular oedema accounts for 41% of visual impairment and 29% of blindness in uveitis (Levin 2014; Rothova 1996). The impact of UMO on visual acuity is usually assessed using standard distance visual acuity charts, either a Snellen chart or an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Acuities from Snellen charts are usually reported either as ‘number of letters read’ or converted into a LogMAR fraction. Although certain visual acuities are considered to be equivalent (e.g. 0.0 LogMAR = 6/6 UK Snellen = 20/20 US Snellen), these equivalences are approximate due to intrinsic differences between the charts (Kaiser 2009). Although the Snellen chart is still widely used in clinical practice, most trials use ETDRS charts due to various methodological advantages. Traditionally, macular oedema has been assessed clinically using stereoscopic slit-lamp fundus biomicroscopy and fluorescein angiography, an invasive procedure requiring intravenous dye and stereo photography imaging testing (Brown 2004). More recently a non-invasive imaging technique, optical coherence tomography (OCT), has become a standard clinical practice in monitoring treatment response and follow-up of UMO (Karim 2013; Reinthal 2004). OCT may be more sensitive than clinical measures in detecting the presence of UMO and provides accurate measures of the structural changes in term of macular thickness (Kempen 2013).
Description of the intervention

There are a wide range of pharmacological treatments for UMO. Corticosteroids are the mainstay of acute treatment (Davis 2010), with alternative routes of administration including; systemic (oral, intravenous and intramuscular); local, which includes periocular injection (sub-Tenon and orbital floor injection); and intraocular (intravitreal injection or implant) (Kok 2005; Venkatesh 2008). For long-term treatment it is important to reduce corticosteroid usage, leading to the use of ‘second-line’ therapies, which are typically immunomodulatory and include T-cell inhibitors (e.g. ciclosporin, and tacrolimus) and anti-metabolites (e.g. azathioprine, methotrexate, mycophenolate mofetil). Alkylating agents (e.g. cyclophosphamide) have traditionally been used as a ‘third line’ for severe refractory disease (Barry 2014; Deuter 2009; Markomichelakis 2004; Neri 2008; Taylor 2009). Anti-vascular endothelial growth factor (VEGF) agents and oral carbonic anhydrase inhibitor (acetazolamide) have also occasionally been used to treat UMO (Karim 2013). Anti-tumour necrosis factor (anti-TNF) drugs (the subject of this Cochrane Review) have recently been licensed for the treatment of uveitis (NICE 2017); adalimumab has been approved as an option for treating non-infectious uveitis in the posterior segment of the eye in adults in cases of severe disease that demonstrates an inadequate response or tolerance to immuno-suppressant therapy. Historically, anti-TNF agents have commonly been used off-licence, after the failure of one or more second-line agents, but before the use of an alkylating agent (Sharma 2009).

Anti-TNF drugs are biological agents that selectively block the actions of TNF, a critical cell-signalling molecule (cytokine) in the inflammatory process (Deuter 2009; McCluskey 2000). Originally pioneered in the 1990s for use in rheumatoid arthritis (RA), anti-TNF drugs are now central to the treatment of many inflammatory diseases including RA, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis (AS), Crohn’s disease (Sharma 2009), and Behçet’s disease (Hatemi 2008). As noted earlier, most non-infectious uveitis is immune mediated and is commonly associated with many of these same systemic diseases (Lee 2014a; Lee 2014b; Murphy 2004; Takeuchi 2013).

There are currently five anti-TNF agents licensed for a range of non-ocular inflammatory diseases; none are licensed for ophthalmic use (Scallon 1995; Scallon 2002). The first anti-TNF agent to be developed for clinical use was infliximab, a chimeric IgG1 that binds to soluble and membrane TNF-α, preventing TNF-α from binding to its receptor in the cell (Wooley 1995). The main route of administration is intravenous (Markomichelakis 2004). The second anti-TNF agent to reach clinical usage was etanercept. This is a soluble protein linked to the human Fc fragment of IgG1 that prevents TNF-α and β from interacting with their receptor; its route of administration is subcutaneous (Jabs 2001). The third anti-TNF drug is adalimumab, which is a humanised IgG monoclonal antibody that binds to human TNF-α (Kaymakcalan 2009). Adalimumab is administered subcutaneously (Rudwaleit 2009). In addition to direct effects on the TNF-pathways, downstream effects appear to include an increase in regulatory T cells and modulation of vascular endothelial growth factor (VEGF)-mediated pathways (Eckens 2011). Golimumab is a human monoclonal antibody to TNF-α with the advantage of requiring only monthly subcutaneous injection (Cordero-Coma 2015; Feaz 2014; Misericocchi 2014). Certolizumab consists only of the pegylated humanised Fab fragment of a monoclonal antibody directed against TNF-α. It is administered subcutaneously once every two weeks (Sánchez-Cano 2013; Tlucek 2012). Both agents have shown benefits for ocular inflammatory disease; however, existing data are limited to case reports and case series (Mesquida 2013).

Although people with uveitis have received treatment with other anti-TNF drugs, the most commonly used anti-TNF agents are the monoclonal antibodies infliximab and adalimumab; in addition to the standard systemic administration, some authors have reported intravitreal administration (Pascual-Camps 2014; Schaap-Fogler 2014). Some people with uveitis have also received other anti-TNF drugs for uveitis.

How the intervention might work

The pathogenesis of the UMO is related to the underlying ocular inflammatory process (uveitis) causing release of inflammatory mediators including interleukin (IL)-1, IL-2, IL-6, IL-8, and TNF-α, transforming growth factor (TGF)-β and interferon (IFN)-γ, many of which directly or indirectly contribute to disruption of the blood-retina barrier. As a result, protein and large molecules are trapped within the retina, causing fluid flow out of the vessels via the osmotic gradient (Curnow 2006; Van Kooij 2006).

TNF-α, a key pro-inflammatory cytokine in a range of inflammatory conditions, has proven pivotal in animal models of uveitis and is present in intraocular fluids in human uveitis (Foxman 2002; Murphy 2004). It is a pleiotropic cytokine produced by a number of cells and has an important role in a range of leukocyte functions (Feldmann 2005; Sifakis 2004). Specific roles include: increasing leukocyte recruitment to the eye via induction of chemokines and increased leukocyte adhesion to vascular endothelium; dendritic cell maturation to increase the effectiveness of their antigen presentation and cytokine production; macrophage activation and enhancing T-cell activation. TNF-α may also be pro-apoptotic for both infiltrating and resident cells (Cordero-Coma 2015). The exact cascade of inflammatory mediators that leads to UMO is not well understood (Curnow 2006; Schaap-Fogler 2014); however, there is agreement that TNF-α upregulates VEGF production in choroidal endothelial cells, and TNF-α blockade is associated with a reduction in serum VEGF levels (Calleja 2012; Giraud 1998; Hangai 2006).
Why it is important to do this review

UMO is the leading cause of sight loss in uveitis and a major cause of blindness in the working-age population. There is mechanistic data to support the proposal that anti-TNF drugs may provide more targeted disease control of uveitis than provided by current non-biological therapies, and there is evidence demonstrating significant benefit of anti-TNF drugs in related systemic inflammatory conditions. Off-licence use of anti-TNF agents for uveitis has become common in some centres, but there is a lack of national guidelines or consensus statements and considerable variation in practice (Davis 2010; Karim 2013; Sreekantam 2011). This review will assess the effects of the anti-TNF therapy in the management of UMO. It is timely to review the literature in order to evaluate and summarise the available evidence for anti-TNF therapy used for the treatment of UMO, which may form the basis of evidence-based clinical recommendations.

OBJECTIVES

To assess the effects of anti-TNF therapy for UMO.

METHODS

Criteria for considering studies for this review

Types of studies

We planned to include all relevant randomised controlled trials (RCTs) assessing anti-TNF therapy for treating UMO.

Types of participants

We planned to include trials with participants of any age, sex or ethnicity with a diagnosis of UMO.

Types of interventions

The primary comparisons of this review were:

- anti-TNF versus no treatment or placebo;
- anti-TNF versus another pharmacological agent;
- comparison of different anti-TNF drugs;
- comparison of different doses and routes of administration of the same anti-TNF drug.

Types of outcome measures

We planned not to select studies based on outcomes. However, we planned to consider clinical and patient-reported outcomes to be important for the aims of the review. We planned to classify outcomes as primary and secondary as follows.

Primary outcomes

The primary outcome measure for this review was best corrected visual acuity (BCVA) in the treated eye. This was measured in the following ways.

- Mean change in LogMAR BCVA between baseline (before treatment) and at the pre-specified time points.
- The proportion of participants gaining 5 or more ETDRS letters (equivalent to 1 ETDRS line or 0.1 LogMAR improvement) at the follow-up visit in the treated eye at the pre-specified time point.
- The proportion of participants losing 5 or more ETDRS letters (equivalent to 1 ETDRS line or 0.1 LogMAR worsening) recorded at the follow-up visit in the treated eye at the pre-specified time point.

Secondary outcomes

Anatomical macular change

We planned to record anatomical changes in macular structure as studies measured them.

- Mean change in central macular thickness (CMT) in microns, as assessed by OCT at pre-specified time points.
- Proportion with clinical resolution of UMO, as assessed by stereoscopic slit-lamp fundus biomicroscopy (clinical) at pre-specified time points.
- Proportion with angiographic resolution of UMO, as assessed by fundus fluorescein angiography at pre-specified time points.

Clinical estimation of vitreous haze

- Changes in vitreous haze, as assessed by stereoscopic fundus indirect biomicroscopy examination at pre-specified time points.

Health-related quality of life

- Mean change in quality-of-life score (both vision-related and non-vision-related), as measured by any validated quality-of-life questionnaire at the pre-specified time points.
Adverse events

- We planned to record all adverse events reported in the included studies at the pre-specified time points.

We expected data to be available at multiple time points within and between studies. We planned to categorise nominal data from each analysis into three groups. We planned to group the post-intervention time points for assessment of outcomes into three different time ranges: 3 months or less; more than 3 months and up to 6 months; and more than 6 months.

Search methods for identification of studies

Electronic searches

The Cochrane Eyes and Vision Information Specialist searched the following electronic databases for randomised controlled trials and controlled clinical trials. There were no language or publication year restrictions. The date of the search was 29 March 2018.

- Cochrane Central Register of Controlled Trials (CENTRAL; 2018, Issue 3), which contains the Cochrane Eyes and Vision Trials Register, in the Cochrane Library (latest issue) (Appendix 1)
- MEDLINE Ovid (1946 to 29 March 2018) (Appendix 2)
- Embase Ovid (1947 to 29 March 2018) (Appendix 3)
- Web of Science Conference Proceedings Citation Index-Science (CPCI-S) (1970 to 29 March 2018) (Appendix 4)
- System for Information on Grey Literature in Europe (OpenGrey) (www.opengrey.eu/ to 29 March 2018) (Appendix 5)

Searching other resources

We planned to search the reference lists of potentially relevant studies to identify any additional trials. We did not handsearch conference proceedings or journals for this review.

Data collection and analysis

Selection of studies

We carried out the study selection process in two stages.

- First, we screened the title and the abstract of identified articles in order to remove irrelevant records, excluding articles that obviously did not meet the selection criteria.
- Secondly, we planned to retrieve the full-text of any potentially relevant articles and assess them against the selection criteria.

At both stages, two review authors (MT and RB) independently assessed articles, resolving any disagreements by discussion and if required by referral to a third review author (DM). Two review authors independently screened the titles and abstracts resulting from the searches using web-based software Covidence (Covidence). We have illustrated the study selection processes using a PRISMA flow diagram (Moher 2010).

We planned to have non-English language articles translated in part or in full to aid study selection and analysis. As we did not identify any published RCTs for inclusion in our review, we were not able to complete the steps for data extraction or analysis. In future updates, if we find any RCTs that meet our inclusion, we will follow the process outlined below.

Data extraction and management

See: Appendix 9

Two review authors (MT and RB) will extract data independently using an online data extraction form in Covidence (Covidence). We will resolve any discrepancies through discussion and referral to a third review author (DM) if needed. We will use a standardised piloted data extraction form. We may contact study authors for further information. We will enter all data into Review Manager 5 (RevMan 5) software (Review Manager 2014). For each study, we will extract at least the following information.

- Study characteristics
  - Authors, publication year, title and journal
  - Study design
  - Setting
  - Sample size
  - Length of follow-up
  - Analysis
- Participant characteristics
  - Selection/recruitment criteria
  - Demographic data; number, age, sex, socioeconomic status and ethnicity
  - Type of uveitis (anatomical categorisation, syndrome/aetiological classification)
  - Comorbidity
  - Co-medication
- Intervention and comparator
  - Pharmacological agents
  - Regimen (dose, frequency of administration, route of administration)
  - Comparator details
• Any difference in underlying care between treatment groups
• Outcomes and findings
  o Outcomes measured and results for each outcome including precision and statistical test results
  o Completeness of follow-up for each outcome

Assessment of risk of bias in included studies
Two review authors will independently assess the quality of included studies, resolving disagreements through discussion and referral to a third review author (DM) if required. We will employ the methods set out in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Intervention (Higgins 2017).
We will consider the following domains.
• Selection bias: allocation concealment bias, randomisation sequence generation bias
• Performance bias: masking (or blinding) of study participants and the researcher
• Detection bias: masking (or blinding) of outcome assessors
• Attrition bias: loss to follow-up and rate of compliance in both groups (withdrawals from the study lead to incomplete outcome data)
• Reporting bias: selective outcome reporting

We will report the ’Risk of bias’ domains as being at low risk, high risk or unclear risk (lack of information or uncertainty of potential bias) (Higgins 2017). We will add data from the included studies on risk of bias into Review Manager 2014.

Measures of treatment effect

Continuous data
We will report continuous variables as mean differences with their corresponding 95% confidence intervals.

Dichotomous data
We will report dichotomous variables as risk ratios (RRs) with their corresponding 95% confidence intervals.

We are likely to present results for some outcomes using a number of different measures/statistics measured within and between studies. For example, studies might report visual acuity in metres or feet (from Snellen charts), a LogMAR score, or number of letters or lines read (from ETDRS charts). Investigators may report the change in acuity as a change in any one of these indices or categorised against a threshold, for example, proportion of participants with change greater than or equal to a specific number of lines/letters read (Kaiser 2009). Thus, different studies may consider visual acuity to be continuous data (e.g. group mean LogMAR score), discrete data (e.g. number of lines read) or dichotomous data (e.g. proportion of participants reading x lines, or proportion with a LogMAR score greater than y). It is likely that continuous and dichotomous data will be most common. We will consider converting data between formats to maximise the data available for each analysis (for example, if authors state the type of chart, we might convert letters into lines; interchange LogMAR score and letters; and approximate Snellen UK, US and ETDRS data). We will undertake any conversion of data with due caution, taking into account known issues (Kaiser 2009). We will explicitly acknowledge the impact of any converted data on findings and explore this aspect through sensitivity analysis.
We will also analyse secondary outcome measures, presenting CMT as mean difference with 95% confidence intervals. We will pool health-related quality of life from the same scales using mean difference, and when studies use different scales to assess the same underlying concepts/domains, we will use standardised mean difference.
For adverse events reported in the included studies, we will record counts and rates. We may consider these data as continuous if the adverse events are common and occur often (presented as mean difference) or dichotomous data if the adverse events occur rarely (presented as rate ratio).

Unit of analysis issues
Clinical trials in ophthalmology may randomise one or both eyes of participants to the intervention. The unit of randomisation may depend on the intervention.
• If the intervention is systemic (IV or SC) then the unit of randomisation in the studies will be the participant.
• If the intervention is intraocular - then the unit of randomisation could be the participant or the eye.

The unit of analysis might also depend on the outcome.
• For most outcomes related to vision, our primary unit of analysis will be the eye.
• For outcomes related to things like quality of life, the unit of analysis will be the participant.
• For adverse events, the unit of analysis will be the participant (and/or the eye in case of intraocular administration).

If studies include only one eye from each participant, the unit of analysis can either be the eye or the person. If two eyes from each participant receive the same intervention, and study authors report them as a single unit (either through only one eye used in analysis, or as the average outcome for the two eyes), then the unit of analysis will be the participant.
If studies include two eyes per participant, with no differences in treatment between eyes, and they analyse them as two eyes, the outcome in each eye is likely to be more similar to the outcome in the companion eye than the eye of a different participant; therefore the study design could/should be considered as comparable to a cluster-randomised study.
If the intervention is intraocular administration, and participants receive different treatments in each eye (e.g. paired-eye/within-person design), we can compare outcomes between the two eyes and assess within-person differences if data are available. However, if the study includes more than one eye from some participants but not all participants, and the unit of analysis is the eye, then we should record this, as there are issues with unit of analysis that may not be resolvable. There are inadequate data available to know whether the intravitreal injection of anti-TNF agents may result in therapeutically significant systemic levels. On this basis, we will include any within-person (paired-eye) studies for intravitreal anti-TNF but report them separately.

**Dealing with missing data**
We will assess all the included studies for number of participants excluded or lost to follow-up. For unclear or missing required information in study reports (e.g. on features such as study methods, outcome data, and measures of data variation), we will contact study authors. However, if the study authors do not respond within four weeks or are not able to provide the additional data, we will conduct analyses based on the best available information. We will identify the distribution of missing data between the two arms and discuss the potential impact of missing data on the findings of the review.

**Assessment of heterogeneity**
We will assess clinical and methodological heterogeneity to determine whether studies are sufficiently similar for each comparison/outcome to ensure that data pooling by meta-analysis is appropriate (Higgins 2002; Huedo-Medina 2006). If we combine studies in a meta-analysis, where appropriate we will report the I² statistic (Higgins 2003), which gives the percentage of the total variability in the data due to between-study heterogeneity, and the Tau² statistic, which gives an estimate of the between-study variance (Higgins 2017).

**Assessment of reporting biases**
We will examine selective outcome reporting by comparing outcomes reported in included studies and the outcomes recorded in study protocols. If the protocols are not publicly available, we will contact study authors to supply them. For each meta-analysis containing 10 or more studies, we will construct a funnel plot and assess asymmetry in the plotted data (Peters 2008). Any asymmetry may imply possible publication bias, poor reporting of small studies, true heterogeneity or chance.

**Data synthesis**
We will assess the consistency of clinical and methodological study characteristics, and if there is no substantial heterogeneity between the trials, we will combine results in a meta-analysis using a random-effects model. If there is substantial clinical or statistical heterogeneity, we will not combine study results in meta-analysis but will present data in a narrative summary.

**Subgroup analysis and investigation of heterogeneity**
We will consider subgroup analysis for clinical and anatomical classification of uveitis (anterior, intermediate, posterior and panuveitis) where deemed appropriate.

**Sensitivity analysis**
We will perform sensitivity analysis to assess the robustness of the results and the effect of excluding trials judged to have a high risk of bias in one or more domains.

**'Summary of findings' table and GRADE**
If sufficient data are available, we will produce a 'Summary of findings' table for outcomes at six months' follow-up to provide key information concerning the quality of evidence, the magnitude of effect of the interventions examined, and the sum of available data on all of the primary and secondary outcomes for a given comparison. Two review authors will independently use the GRADE tool to assess the certainty of the evidence in the included studies (GRADEpro GDT). The GRADE system entails an assessment of the quality of a body of evidence for each individual outcome. We will resolve any discrepancies by discussion and refer to a third review author if needed. The table of results will include the primary outcome for the review, which will be the BCVA, using either the mean change in LogMAR BCVA from baseline at the prespecified time point or the proportion of participants gaining 5 or more ETDRS letters from baseline BCVA. In addition, the tables will include results for the following outcomes.
- Mean change in CMT from the baseline at the pre-specified time point
- Proportion of eyes with absence of dye leakage on fluorescein angiography
- Mean change in vitreous haze from the baseline
- Mean change in quality-of-life score
- Proportion of participants with adverse events

**RESULTS**

**Description of studies**

**Results of the search**
The electronic searches yielded 423 records (Figure 1). The Cochrane Information Specialist removed 81 duplicate records and we screened the remaining 342 reports for potential inclusion in the review. We obtained two full-text reports for further assessment, however these did not meet the inclusion criteria, see Characteristics of excluded studies for details. We did not identify any ongoing studies from searches of the trials registers.
Figure 1. Study flow diagram

423 records identified through database searching

342 records after duplicates removed

342 records screened by the authors

340 records excluded

2 full-text reports assessed for eligibility

2 full-text reports excluded, with reasons

No studies included in qualitative synthesis

No studies included in quantitative synthesis (meta-analysis)
Included studies
We found no studies that met the inclusion criteria for this review.

Excluded studies
We excluded two studies on patients with uveitis because they did not report relevant outcomes separately for any participants with UMO (Jaffe 2016; Nguyen 2016).

Risk of bias in included studies
We found no studies that met the inclusion criteria for this review.

Effects of interventions
We found no studies that met the inclusion criteria for this review.

DISCUSSION

Summary of main results
We conducted a search of several electronic literature databases to identify randomised or quasi-randomised trials that evaluated the role of anti-TNF therapy in the management of UMO. Despite using a sensitive search strategy, we did not identify any such trials. Our search highlighted the lack of rigorous evidence to guide the use of anti-TNF therapy in the management of UMO, and identifies a need for further work in this area.

Quality of the evidence
We did not identify any trials for inclusion in this review.

Potential biases in the review process
We aimed to minimise potential biases in the review process by conducting a highly sensitive search for trials, and following rigorous methods as recommended by Cochrane (Lefebvre 2011).

Agreements and disagreements with other studies or reviews
A few non-randomised studies supported the use of anti-TNF agents in the treatment of UMO. However, we did not include such studies in this review, and have not conducted a comprehensive search and critical appraisal of evidence from non-randomised studies.

In a retrospective review of patients with macular oedema secondary to birdshot chorioretinopathy, Steeple 2017 demonstrated adalimumab to be effective in reducing CMT over a 12-month period. Calvo-Rio 2014 demonstrated a similar beneficial effect of adalimumab in a cohort of patients with refractory macular oedema secondary to Behcet’s Disease. Schaap-Fogler 2014 reported outcomes of adalimumab in adults with macular oedema...
due to non-infectious uveitis of varying aetiologies, suggesting that maximum improvement in CMT was observed at six months, however the treatment effect had lessened by 12 months’ follow-up, whilst Markomichelakis 2004 demonstrated an improvement in CMT with infliximab therapy, which was maintained to six months’ follow-up.

In summary, whilst these non-randomised reviews suggest that anti-TNF therapy is indeed effective in the treatment of UMO, they do not provide definitive evidence of treatment benefit.

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

Uveitic macular oedema (UMO) remains a blinding manifestation of ocular inflammatory disease. Preservation of visual function is dependent on achieving rapid disease control, with early restoration of macular anatomy in an attempt to avoid irreversible loss of photoreceptors in this area. Whilst the aetiology of uveitis remains unknown in the majority of cases, the mainstay of treatment remains suppression of the intra-ocular immune system; unfortunately this necessitates systemic immune suppression in most cases, and thus there is a need to identify targeted treatment modalities to avoid unwanted systemic effects. Anti-tumour necrosis factor (TNF) agents have been demonstrated to be well-tolerated and highly effective in the management of uveitis (Jaffe 2016; Nguyen 2016), such that adalimumab is now licensed for this purpose in the UK (NICE 2017). Adalimumab is currently licensed for use as a third-line agent, following development of tolerance or failure to respond to second-line, steroid-sparing agents; it is unclear whether earlier introduction of anti-TNF agents would confer additional benefit in management of UMO and preservation of visual function.

**Implications for research**

Our systematic review demonstrates the need for high-quality, randomised controlled trials (RCTs) to determine the role of anti-TNF agents in UMO. Adalimumab is already licensed for use in uveitis and its efficacy has been assessed through RCTs. Unfortunately published data reports time-to-treatment-failure analyses (Jaffe 2016; Nguyen 2016), and does not specifically address development of UMO, or resolution of UMO in uveitic patients using anti-TNF therapy. With the widespread use of retinal imaging, it would be relatively easy to include CMT (measured by optical coherence tomography (OCT)), or presence/absence of macular oedema (measured by OCT, OCT-angiography or fundus fluorescein angiography) to future studies to enable us to address this important question.

We also acknowledge that whilst UMO is an important complication of disease, uveitis is associated with many significant structural and functional complications. In clinical practice, treatment efficacy is determined with reference to the full range of disease complications experienced by the patient. Making management decisions with consideration of only a single outcome measure may miss important treatment effects on other disease manifestations. We therefore recommend that future reviews of therapeutic interventions in uveitis should use composite measures of treatment response comprising a range of potential complications of disease.

**ACKNOWLEDGEMENTS**

Cochrane Eyes and Vision (CEV) created and executed the electronic search strategies. We thank Anupa Shah, Managing Editor for CEV for help during the review process. We thank Peter Adislon and Jennifer Evans for their comments on the protocol and review.

**REFERENCES**

**References to studies excluded from this review**

**Jaffe 2016 (published data only)**


**Nguyen 2016 (published data only)**


**Additional references**

**Abdulaal 2015**


**Acharya 2013**


**Barry 2014**


Bloch-Michel 1987

Brown 2004

Calleja 2012

Calvo-Río 2014

Cordero-Coma 2015

Covidence [Computer program]

Curnow 2006

Davis 2010

De Smet 2010

Deschenes 2008

Deuter 2009

Durrani 2004

Eckens 2011

Feaz 2014

Feldmann 2005

Foxman 2002

Giraudo 1998

Glanville 2006

GRADEpro GDT [Computer program]

Gritz 2004

Hangai 2006
Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis (Review)

Lardenoye 2006

Lee 2014a

Lee 2014b

Lefebvre 2011

Levin 2014

Markomichelakis 2004

McCluskey 2000

Mesquida 2013

Miserocchi 2014

Moher 2010

Murphy 2004
Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis (Review)

Neri 2008

NICE 2017

Pascual-Camps 2014

Peters 2008

Rao 2013

Reinthal 2004

Review Manager 2014 [Computer program]

Rothova 1996

Rudwaleit 2009

Scallon 1995

Scallon 2002

Schaap-Fogler 2014

Sfikakis 2004

Sharma 2009

Sreekantam 2011

Steeples 2017

Suhler 2008

Sánchez-Cano 2013

Takeuchi 2013

Taylor 2009

Tlucek 2012

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Van Gelder 1999

Van Kooij 2006

Venkatesh 2008

William 2007

Wooley 1995

References to other published versions of this review

Tallouzi 2017

* Indicates the major publication for the study
CHARACTERISTICS OF STUDIES

Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jaffe 2016</td>
<td>Results presented as time to treatment failure (uveitis flare); no subgroup analysis of participants with macular oedema</td>
</tr>
<tr>
<td>Nguyen 2016</td>
<td>Results presented as time to treatment failure; no subgroup analysis of participants with macular oedema</td>
</tr>
</tbody>
</table>

APPENDICES

Appendix 1. CENTRAL search strategy

#1 [mh “Macular Edema”]
#2 [mh “Macula Lutea”]
#3 macula* near/3 oedema
#4 macula* near/3 edema
#5 UMO
#6 maculopathy*
#7#1 or #2 or #3 or #4 or #5 or #6
#8 [mh uveitis]
#9 uveiti*
#10 iritis
#11 iridocycliti*
#12 anterior near/2 scleriti*
#13 pars planitis
#14 retinochoroidit* or choroidit*
#15 Bechet* or Vogt or Koyanagi or Harada or Fuch*
#16 [mh retinitis]
#17 retinitis or neuroretinitis
#18 uveoretinitis or uveo retinitis
#19 vitritis or panuveitis or panophthalmiti*
#20 ophthalm* near/2 sympathetic
#21 [mh “arthritis juvenile rheumatoid”]
#22 juvenile near/2 rheumatoid near/2 arthriti*
#23 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22
#24 [mh “Tumor Necrosis Factor-alpha”]
#25 [mh “Antibodies, Monoclonal”]
#26 [mh “Antibodies, Monoclonal, Humanized”]
#27 [mh Infliximab]
#28 [mh Ádalimumab]
#29 [mh Étanercept]
#30 [mh “Certolizumab Pegol”]
#31 remicade* or humira* or enbrel* or golimumab* or simponi* or cimzia*
Appendix 2. MEDLINE Ovid search strategy

1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. (group or groups).ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. Macular Edema/
14. Macula Lutea/
15. (macula$ adj3 oedema).tw.
17. UMO.tw.
18. maculopathy.$tw.
19. or/13-18
20. exp uveitis/
21. uveitis.$tw.
22. iritis.tw.
23. iridocyclitis.$tw.
25. pars planitis.tw.
26. (retinochoroiditis$ or choroiditis$).tw.
27. (Bechtet$ or Vogt or Koyanagi or Harada or Fuch$).tw.
28. exp retinitis/
29. (retinitis or neuroretinitis).tw.
30. (uveoretinitis or uveoretinitis).tw.
31. (vitreitis or panuveitis or panophthalmitis$).tw.
32. (ophthalm$ adj2 sympathetic).tw.
33. arthritis juvenile rheumatoid/
34. (juvenile adj2 rheumatoid adj2 arthriti$).tw.
35. or/20-34
36. Tumor Necrosis Factor-alpha/
37. Antibodies, Monoclonal/
38. Antibodies, Monoclonal, Humanized/
39. Infliximab/
40. Adalimumab/
41. Etanercept/
42. Certolizumab Pegol/
43. (remicade$ or humira$ or enbrel$ or golimumab$ or simponi$ or cimzia$).tw.
44. or/36-43
45. 19 and 35 and 44
46. 12 and 45

The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy

1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula edema/
34. eye edema/
35. (macula$ adj3 oedema).tw.
36. (macula$ adj3 edema).tw.
37. UMO.tw.
38. maculopathy$.tw.
39. or/33-38
40. exp eye inflammation/
41. uveiti$.tw.
42. iritis.tw.
43. iridocycliti$.tw.
44. (anterior adj2 scleriti$).tw.
45. pars planitis.tw.
46. (retinochoroidit$ or choroidit$).tw.
47. (Bechet$ or Vogt or Koyanagi or Harada or Fuch$).tw.
48. (retinitis or neuroretinitis).tw.
49. (uveoretinitis or uveo retinitis).tw.
50. (vitritis or panuveitis or panophthalmiti$).tw.
51. (ophthalm$ adj2 sympathetic).tw.
52. arthritis juvenile rheumatoid/
53. (juvenile adj2 rheumatoid adj2 arthritic$).tw.
54. or/40-53
55. exp tumor necrosis factor alpha/
56. antibodies, monoclonal, humanized/
57. monoclonal antibody/
58. Infliximab/
59. Adalimumab/
60. Etanercept/
61. Certolizumab Pegol/
62. (remicade$ or humira$ or enbrel$ or golimumab$ or simponi$ or cimzia$).tw.
63. or/55-62
64. 39 and 54 and 63
65. 32 and 64

Appendix 4. Web of Science CPCI search strategy
#10 #9 AND #8 AND #3
#9 TS=(Infliximab OR Adalimumab OR Etanercept OR Certolizumab NEAR/1 Pegol OR remicade* OR humira* OR enbrel* OR golimumab* OR simponi* OR cimzia*)
#8 #4 OR #5 OR #6 OR #7
#7 TS=(vitritis OR panuveitis OR panophthalmiti* OR ophthalm* NEAR/2 sympathetic OR juvenile NEAR/2 rheumatoid NEAR/2 arthritic*)
#6 TS=(retinochoroidit* OR choroidit* OR Bechet* OR Vogt OR Koyanagi OR Harada OR Fuch* OR retinitis OR neuroretinitis OR uveoretinitis OR uveo NEAR/1 retinitis)
#5 TS=(pars NEAR/1 planitis OR anterior NEAR/2 scleriti*)
#4 TS=(uveiti* OR iritis OR iridocycliti*)
#3 #1 OR #2
#2 TS=(UMO OR maculopath*)
#1 TS=(macula* NEAR/3 oedema OR macula* NEAR/3 edema OR macula* NEAR/3 lutea)

Appendix 5. OpenGrey search strategy
(macular oedema OR uveitis) AND (infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab)

Appendix 6. ISRCTN search strategy
"( Condition: macular oedema OR uveitis AND Interventions: infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab )"

Appendix 7. ClinicalTrials.gov search strategy
macula edema OR uveitis | (infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab)
Appendix 8. WHO ICTRP search strategy

macular oedema OR uveitis = CONDITION AND infliximab OR adalimumab OR etanercept OR golimumab OR certolizumab = INTERVENTION

Appendix 9. Data on study characteristics

<table>
<thead>
<tr>
<th>Mandatory items</th>
<th>Optional items</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td></td>
</tr>
<tr>
<td>Study design</td>
<td></td>
</tr>
<tr>
<td>· Parallel-group RCT i.e. people randomised to treatment</td>
<td>Exclusions after randomisation</td>
</tr>
<tr>
<td>· Within-person RCT i.e. eyes randomised to treatment</td>
<td>Losses to follow-up</td>
</tr>
<tr>
<td>· Cluster-RCT i.e. communities randomised to treatment</td>
<td>Number randomised/analysed</td>
</tr>
<tr>
<td>· Cross-over RCT</td>
<td>How were missing data handled? e.g. available-case analysis, imputation methods</td>
</tr>
<tr>
<td>· Other, specify</td>
<td>Reported power calculation (Y/N), if yes, sample size and power</td>
</tr>
</tbody>
</table>

| Eyes or Unit of randomisation/ unit of analysis | |
| · One eye included in study, specify how eye selected | |
| · Two eyes included in study, both eyes received same treatment, briefly specify how analysed (best/worst/average/both and adjusted for within-person correlation/both and not adjusted for within-person correlation) and specify if mixture one eye and two eye | |
| · Two eyes included in study, eyes received different treatments, specify if correct pair-matched analysis done | |

| Participants | |
| Country | Setting |
| Total number of participants | Ethnic group |
| This information should be collected for total study population recruited into the study. If these data are reported for the people who were followed up only, please indicate. | Equivalence of baseline characteristics (Y/N) |
| Number (%) of men and women | |
| Average age and age range | |
| Inclusion criteria | |
| Exclusion criteria | |

Interventions

21 Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis (Review)

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Interventions

<table>
<thead>
<tr>
<th>Intervention (n = )</th>
<th>Comparator (n = )</th>
</tr>
</thead>
<tbody>
<tr>
<td>See MECIR 65 and 70</td>
<td></td>
</tr>
</tbody>
</table>

- Number of people randomised to this group
- Drug (or intervention) name
- Dose
- Frequency
- Route of administration

### Outcomes

<table>
<thead>
<tr>
<th>Primary and secondary outcomes as defined in study reports</th>
</tr>
</thead>
<tbody>
<tr>
<td>See MECIR R70</td>
</tr>
</tbody>
</table>

- List outcomes
- Adverse events reported (Y/N)
- Length of follow-up and intervals at which outcomes assessed
- Planned/actual length of follow-up

### Notes

<table>
<thead>
<tr>
<th>Date conducted</th>
<th>Sources of funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specify dates of recruitment of participants mm/yr to mm/yr</td>
<td></td>
</tr>
</tbody>
</table>

- Full study name: (if applicable)
- Reported subgroup analyses (Y/N)
- Were trial investigators contacted?

### Contributions of Authors

MT, AD, DM, RB and MC led the development of the protocol. AD, RB and PM provided clinical advice; DM and MC provided methodological advice. NB provided the patient-public perspective. JM gave input in reviewing the protocol. RB and MT screened and reviewed all papers identified in the database search and drafted the review text. All review authors read and approved the final manuscript.

### Declarations of Interest

RB: none known
MT: none known
NB: none known
JM: none known
PM: none known
MC reports receipt of personal fees from Astellas and Takeda and grants from the NIHR, Macmillan Cancer Support, HDRUK and Innovate UK outside the submitted work.

DM: none known
AD: none known
SOURCES OF SUPPORT

Internal sources

- National Institute of Health Research (NIHR), UK.
Melanie Calvert is funded by the NIHR Birmingham Biomedical Research Centre and the NIHR Surgical Reconstruction and Microbiology Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

External sources

- National Institute for Health Research (NIHR), UK.
- This review represents an independent research project funded by the NIHR under the Clinical Doctoral Research Fellowship Scheme being undertaken at the University of Birmingham.
- Richard Wormold, Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges financial support for his CEV research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.
- This review was supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK editorial base.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS) or the Department of Health.